A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
type: MedicalStudy
description: A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE1
start date: 2023-10-02
end date: 2026-02-02
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT06063317
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Imugene Limited
study subject: Solid Tumor, Adult
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Solid Tumor, Adult

AI Analytics
type: Organization